Formulation and Evaluation of Sustained release matrix tablets of Atomoxetine HCl by using Natural and Synthetic Polymers

2020 ◽  
Vol 10 (1) ◽  
pp. 43
Author(s):  
Y. Krishna Reddy ◽  
Fathima Umera
Keyword(s):  
Sustained Release ◽  
Synthetic Polymers ◽  
Matrix Tablets ◽  
Natural And Synthetic

scholarly journals Oral Sustained Release Tablets of Zidovudine Using Binary Blends of Natural and Synthetic Polymers

2010 ◽  
Vol 33 (9) ◽  
pp. 1561-1567 ◽  
Author(s):  
Martins Emeje ◽  
Olajide Olaleye ◽  
Christiana Isimi ◽  
Joseph Fortunak ◽  
Stephen Byrn ◽  
...  
Keyword(s):  
Sustained Release ◽  
Synthetic Polymers ◽  
Binary Blends ◽  
Sustained Release Tablets ◽  
Natural And Synthetic

scholarly journals Formulations of sustained release matrix tablets of Furosemide using natural and synthetic polymers

2021 ◽  
Vol 11 (5) ◽  
pp. 105-109
Author(s):  
Shivani Soni ◽  
Vivek Jain ◽  
Sunil Kumar Jain ◽  
Pushpendra Kumar Khangar
Keyword(s):  
Sustained Release ◽  
Xanthan Gum ◽  
Dosage Form ◽  
Spectroscopic Method ◽  
Synthetic Polymers ◽  
Matrix Tablets ◽  
Matrix Tablet ◽  
Direct Compression ◽  
The Matrix ◽  
Pharmaceutical Industries

The primary benefit of a sustained release dosage form compared to a conventional dosage form, is the consistent drug plasma concentration and consequently uniform therapeutic effect. Matrix system are preferential because of their ease, patient compliance etc, than  traditional drug delivery which have several drawbacks like reiterated administration, variation in blood concentration level etc. The aim of the present research study was to develop and evaluate sustained release matrix tablets of furosemide using direct compression method using  natural  gummy  and  waxy  materials (Xanthan  gum, bees  wax)  and synthetic  polymers  (HPMC K4M). The matrix tablet formulations were prepared by using different drug: polymer ratios (1:1, 1:2 and 1:3). All formulations were assessed using micromeritics studies of powder blend and diverse physicochemical tests. All the physicochemical characters of the formulated tablets were within acceptable limits. The release pattern of the drug was viewed over a period of 12 hours and determined the amount of drug by the UV-Visible spectroscopic method. Dissolution data demonstrated that the formulated tablets with Xanthan gum and hydroxyl propyl methylcellulose (HPMC) provided sustained release of the drug up to 12 hrs. Therefore inexpensively it may be appropriate for the pharmaceutical industries to employ this kind of simple technologies for the expansion of advanced formulations. Hence, we conclude that the purpose of this study was to formulate a sustained release matrix tablet of furosemide using diverse polymers and their dissimilar proportions have been attained. Keywords: Furosemide, Direct compression, Natural, Synthetic polymers, Sustained release tablets.

scholarly journals Effect of Granulation Methods on Drug Release Studies in Sustained Release Matrix Tablets of a Poorly Soluble Drug prepared using Synthetic Polymers

2020 ◽  
Vol 10 (3) ◽  
pp. 76-82
Author(s):  
Lakshmi Usha Ayalasomayajula ◽  
E. Radha Rani ◽  
A.V.S. Ksheera Bhavani ◽  
A. Vyasa Murty
Keyword(s):  
Drug Release ◽  
Sustained Release ◽  
Solid Dispersions ◽  
D2 Receptor ◽  
Synthetic Polymers ◽  
Solvent Evaporation ◽  
Matrix Tablets ◽  
Polymer Mixture ◽  
Wet Granulation ◽  
Direct Compression

Vomiting or emesis is the abnormal emptying of stomach and upper part of intestine through esophagus and mouth. It occurs due to stimulation of the emetic (vomiting) centre situated in the medulla oblongata. Domperidone, a D2 receptor antagonist has antiemetic and prokinetic action is used as a model drug in the present work to prepare Sustained release matrix tablets using various synthetic polymers like Eudragit and HPMC K15 M. The tablets are designed to have a pH dependent release profile in order to prevent initial drug release in the stomach to reduce the possible gastro-irritant and ulcerogenic effects of the drug. Different polymer and diluent concentrations and various compression techniques like wet granulation technique and direct compression techniques were used in order to release the contents of the tablets in a sustained manner over a certain period of time. Domperidone is BCS Class II drug and its solubility was enhanced by preparing solid dispersions using solvent evaporation technique. In the present work solid dispersions containing drug and polymer mixture in the ratio 1:1 was further formulated into tablets by incorporating various synthetic polymers in three different concentrations. The tablets were prepared using different granulating techniques. Formulation (F3) containing drug and  polymers in the ratio 1:1 prepared by wet granulation technique could sustain the drug release over a period of 12h and hence considering all the post compression parameters it was optimized as the better formulation. FTIR, DSC, X-Ray Diffraction, SEM studies were performed for optimized solid dispersion mixture and also the optimized formulation. Keywords: Solubility enhancement, Solid dispersions, Solvent Evaporation, Wet granulation, Direct Compression.

Effects of release modifier on Carvedilol release from Kollidon SR based matrix

2012 ◽  
Vol 1 (8) ◽  
pp. 186 ◽  
Author(s):  
Urmi Das ◽  
Mohammad Salim Hossain
Keyword(s):  
Drug Release ◽  
Sustained Release ◽  
Microcrystalline Cellulose ◽  
Matrix Tablets ◽  
Dissolution Time ◽  
Release Mechanism ◽  
Matrix Tablet ◽  
Weight Variation ◽  
The Matrix ◽  
Tablet Formulations

<p>Sustained release Carvedilol matrix tablets constituting Kollidon SR were developed in this study in an attempt to investigate the effect of release modifiers on the release profile of Carvedilol from matrix. Three matrix tablet formulations were prepared by direct compression of Kollidon SR in combination with release modifier (HPMC and Microcrystalline Cellulose) and magnesium stearate. Tablets containing only Kollidon SR with the active ingredient demonstrated a rapid rate of drug release. Incorporation of HPMC in the matrix tablet prolonged the release of drug but incorporation of Microcrystalline Cellulose showed superimposable release pattern with an initial burst effect as confirmed by mean dissolution time and Higuchi release rate data. After 7 hours of dissolution, Carvedilol release from the matrix systems were 91.42%, 83.41%, from formulation F1 and F2 respectively. Formulation F3 exhibited 100 % release at 4 hours. All the tablet formulations showed acceptable pharmaco-technical properties and complied with the in-house specifications for tablet weight variation, friability, hardness, thickness, and diameter. Prepared tablets also showed sustained release property for carvedilol. The drug release mechanism from the matrix tablets of F1 and F2 was found to be followed by Fickian and F3 by Non-Fickian mechanism.</p><p>DOI: <a href="http://dx.doi.org/10.3329/icpj.v1i8.11095">http://dx.doi.org/10.3329/icpj.v1i8.11095</a></p> <p>International Current Pharmaceutical Journal 2012, 1(8): 186-192</p>

scholarly journals Development and Bio-Predictive Evaluation of Biopharmaceutical Properties of Sustained-Release Tablets with a Novel GPR40 Agonist for a First-in-Human Clinical Trial

Pharmaceutics ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 804
Author(s):  
Ewelina Juszczyk ◽  
Kamil Kisło ◽  
Paweł Żero ◽  
Ewa Tratkiewicz ◽  
Maciej Wieczorek ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Sustained Release ◽  
Development Strategy ◽  
Matrix Tablets ◽  
Matrix Tablet ◽  
Mechanical Agitation ◽  
Development Cycle ◽  
Dissolution Tests ◽  
Sustained Release Tablets ◽  
Biopharmaceutical Properties

Sustained-release (SR) formulations may appear advantageous in first-in-human (FIH) study of innovative medicines. The newly developed SR matrix tablets require prolonged maintenance of API concentration in plasma and should be reliably assessed for the risk of uncontrolled release of the drug. In the present study, we describe the development of a robust SR matrix tablet with a novel G-protein-coupled receptor 40 (GPR40) agonist for first-in-human studies and introduce a general workflow for the successful development of SR formulations for innovative APIs. The hydrophilic matrix tablets containing the labeled API dose of 5, 30, or 120 mg were evaluated with several methods: standard USP II dissolution, bio-predictive dissolution tests, and the texture and matrix formation analysis. The standard dissolution tests allowed preselection of the prototypes with the targeted dissolution rate, while the subsequent studies in physiologically relevant conditions revealed unwanted and potentially harmful effects, such as dose dumping under an increased mechanical agitation. The developed formulations were exceptionally robust toward the mechanical and physicochemical conditions of the bio-predictive tests and assured a comparable drug delivery rate regardless of the prandial state and dose labeled. In conclusion, the introduced development strategy, when implemented into the development cycle of SR formulations with innovative APIs, may allow not only to reduce the risk of formulation-related failure of phase I clinical trial but also effectively and timely provide safe and reliable medicines for patients in the trial and their further therapy.

Sign in / Sign up

Export Citation Format

Share Document